Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trialMarkus P. Schlaich, Thomas Guldager Lauridsen, M Bellet et al.|The Lancet|2022Cited by 223
Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trialJiang He, Zhaoqing Sun, Liying Xing et al.|The Lancet|2023Cited by 139
Association of Blood Pressure Trajectories in Early Life with Subclinical Renal Damage in Middle AgeWenling Zheng, Zuyi Yuan, Jianjun Mu et al.|Journal of the American Society of Nephrology|2018Cited by 102
Associations of risk factors in childhood with arterial stiffness 26 years laterChao Chu, Yang Wang, Yi Dai et al.|Journal of Hypertension|2017Cited by 59